- Home
- ESPR vs CHPT Comparison
ESPR vs CHPT Comparison
Compare ESPR & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CHPT
- Stock Information
- Founded
- ESPR 2008
- CHPT 2007
- Country
- ESPR United States
- CHPT United States
- Employees
- ESPR N/A
- CHPT N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- ESPR Health Care
- CHPT Consumer Discretionary
- Exchange
- ESPR Nasdaq
- CHPT Nasdaq
- Market Cap
- ESPR 456.6M
- CHPT 483.4M
- IPO Year
- ESPR 2013
- CHPT N/A
- Fundamental
- Price
- ESPR $2.52
- CHPT $1.15
- Analyst Decision
- ESPR Buy
- CHPT Hold
- Analyst Count
- ESPR 3
- CHPT 15
- Target Price
- ESPR $8.17
- CHPT $2.47
- AVG Volume (30 Days)
- ESPR 5.2M
- CHPT 13.4M
- Earning Date
- ESPR 11-07-2024
- CHPT 12-04-2024
- Dividend Yield
- ESPR N/A
- CHPT N/A
- EPS Growth
- ESPR N/A
- CHPT N/A
- EPS
- ESPR N/A
- CHPT N/A
- Revenue
- ESPR $295,451,000.00
- CHPT $441,698,000.00
- Revenue This Year
- ESPR $198.22
- CHPT N/A
- Revenue Next Year
- ESPR $25.83
- CHPT $23.54
- P/E Ratio
- ESPR N/A
- CHPT N/A
- Revenue Growth
- ESPR 187.12
- CHPT N/A
- 52 Week Low
- ESPR $1.16
- CHPT $1.05
- 52 Week High
- ESPR $3.40
- CHPT $3.13
- Technical
- Relative Strength Index (RSI)
- ESPR 64.07
- CHPT 43.45
- Support Level
- ESPR $2.02
- CHPT $1.05
- Resistance Level
- ESPR $2.60
- CHPT $1.15
- Average True Range (ATR)
- ESPR 0.19
- CHPT 0.08
- MACD
- ESPR 0.02
- CHPT 0.00
- Stochastic Oscillator
- ESPR 89.04
- CHPT 27.14
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.